Target
taxanes
44 abstracts
Abstract
Pyrotinib plus taxanes or vinorelbine for human epidermal growth factor receptor 2-positive metastatic breast cancer: A prospective study.Org: Imaging Department, Jiangsu Cancer Hospital Medical Oncology, Jiangsu Cancer Hopistal,
Abstract
Neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Arthralgia in patients with cancer receiving immune checkpoint inhibitor: A systematic review and meta-analysis.Org: University of Hawaii Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, John A. Burns School of Medicine, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Beth Israel,
Abstract
Acupuncture for preventing progression of taxane-induced peripheral neuropathy (ATP): A phase II randomized, placebo-controlled trial.Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
The preliminary efficacy and safety results of neoadjuvant phase 2 study of penpulimab combined with taxanes and carboplatin in triple-negative breast cancer (neoTAPPL).Org: Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Sounthwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Department of Thoracic Surgery, the Eighth Medical Center of Chinese PLA General Hospital, Chongqing, China, Central Medical Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. L., Nanjing, China,
Abstract
A phase I clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and preliminary efficacy of SCB-219M in patients with chemotherapy-induced thrombocytopenia (CIT): An interim analysis.Org: Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Sixth People's Hospital of Chengdu,
Abstract
Effectiveness and safety analysis of serplulimab-based regimens in patients with HER2-negative advanced gastric cancer from a real-world retrospective study.Org: the Fourth Affiliated Hospital of Soochow University,
Abstract
Assessing the feasibility and cost-effectiveness of all oral adjuvant chemotherapy (cyclophosphamide, methotrexate, capecitabine) in high-risk hormone receptor positive breast cancer.Org: University of Illinois Hospital & Health Sciences System, University of Illinois Chicago, Stanford University School of Medicine,
Abstract
A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment (YCT).Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Real-world clinical outcomes and economic burden of early discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer.Org: Asclepius Analytics, IQVIA, Inc.,
Abstract
Improving chemotherapy-induced alopecia for women receiving anthracycline plus taxane chemotherapy using the Paxman scalp cooling system at lower temperatures.Org: Memorial Sloan Kettering Cancer Center, New York, NY, Dermatology Service, NYU Langone Health, New York, NY,
Abstract
Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C.Org: CEPCM AP-HM,
Abstract
Efficacy and safety of mecapegfilgrastim in preventing neutropenia during concurrent chemoradiotherapy.Org: The First Affiliated Hospital of Air Force Military Medical University, Affiliated Hospital of Yangzhou University, Taixing People's Hospital, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology,
Abstract
Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting: Results from the U.S. Expanded Access Program and comparisons with phase 3 VISION data.Org: Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Tulane University School of Medicine,
Abstract
Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial.Org: Centre Léon Bérard, Centre Paul Papin, Lorraine Cancer Institute, Hôpital Européen Georges Pompidou, CHU Hautepierre,
Abstract
An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.Org: University Hospital Leuven, International Breast Cancer Centre (IBCC), Quironsalud Group, Aichi Cancer Center Hospital, Vall d’Hebron University Hospital/VHIO,
Abstract
Cardiac function of long-responders to dual anti-HER2 antibodies amongst patients with HER2 positive advanced breast cancer.Org: Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Queen Elizabeth Hospital, Hong Kong Sanatorium & Hospital,
Abstract
Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.Org: Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).Org: Narayana Multispeciality Hospital, Tata Memorial Hospital, Homi Bhabha cancer hospital and research centre, Regency Hospital, National Cancer Insitute,
Abstract
The impact of renin-angiotensin-aldosterone system inhibitors on immune checkpoint inhibitor-associated adverse cardiovascular events.Org: National Taiwan University Hospital Yunlin Branch, Mount Auburn Hospital, Harvard Medical School, Cambridge University Hospitals NHS Foundation Trust, Taipei TzuChi Hospital,
Abstract
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.Org: Sarah Cannon Research Institute at Tennessee Oncology, PLLC, Hospital General Universitario Gregorio Marañón, Mayo Clinic, European Institute of Oncology, Yonsei Cancer Center, Yonsei University Health System,
Abstract
Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: A single-center, randomized, controlled, phase-II clinical study.Org: Southwest Hospital Army Medical University, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Sounthwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Department of Thoracic Surgery, the Eighth Medical Center of Chinese PLA General Hospital, Chongqing, China, Central Medical Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. L., Nanjing, China,
Abstract
Use of PLR and NLR to evaluate the efficacy and prognosis of neoadjuvant chemotherapy with lobaplatin in triple-negative breast cancer.Org: Southwest Hospital Army Medical University, Army Medical University, Chongqing Precision Biotech, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Sounthwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Department of Thoracic Surgery, the Eighth Medical Center of Chinese PLA General Hospital, Chongqing, China, Central Medical Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. L., Nanjing, China, 29 Gaotanyan Main Street,
Abstract
Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin.Org: Fudan University Shanghai Cancer Center, Cancer Institute of Jiangsu Province, Shanghai Medical College, Fudan University, The Fourth Hospital of Hebei Medical University, The First Hospital of Jilin University, Changchun, Jilin Province, China,
Abstract
Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.Org: Department of Medicine, Duke University School of Medicine, Texas Oncology-Baylor Charles A. Sammons Cancer Center, PIH Health Whittier Hospital, Nebraska Hematology-Oncology P.C., Division of Hematology/Oncology, David Geffen School of Medicine at the University of California Los Angeles/Jonsson Comprehensive Cancer Center,
Abstract
Artificial intelligence (AI) –based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR) –positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study.Org: Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli–IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy, Fondazione Policlinico Universitario "A. Gemelli" - IRCCS - UOC Oncologia Medica, Roma, Italy, Università Cattolica del Sacro Cuore, Roma, Italy, Policlinico Gemelli, Roma, Italy, Fondazione Policlinico Gemelli, Rome, Roma, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, Precision medicine in senology Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy, Fondazione Policlinico Gemelli, Rome, Rome, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy, Universita Cattolica Del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, Italy,
Abstract
Wireless transcutaneous electric nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN): A proof-of-concept, placebo-controlled, randomized clinical trial (RCT).Org: University of Rochester Medical Center Department of Neurobiology and Anatomy, University of Rochester Medical Center, Wilmot Cancer Institute, Cancer Research of Wisconsin and Northern Michigan (CROWN) NCORP, Upstate Carolina NCORP,
Abstract
Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi City,
Abstract
A pilot study of intraneural facilitation versus standard physical therapy for prevention of chemotherapy-induced peripheral neuropathy.Org: Division of Medical Oncology and Hematology, Loma Linda University of Medicine, Loma Linda, CA, Loma Linda University Department of Internal Medicine, Neuropathic Therapy Center, Loma Linda University Health, Cancer Center Clinical Trial Unit, Loma Linda University Health, Loma Linda University School of Nursing,
Abstract
Impact of exercise on chemotherapy-induced peripheral neuropathy (CIPN) in survivors with post-treatment primary breast cancer.Org: Memorial Sloan Kettering Cancer Center, Renaissance School of Medicine at Stony Brook University, School of Health Science, Stockton University,
Abstract
Neoadjuvant chemotherapy followed by definitive chemoradiation in technically unresectable oral cavity squamous cancers.Org: Tata Memorial Hospital (HBNI), Tata Memorial Centre,
Abstract
Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC).Org: N.N. Petrov National Research Oncology Institute, N.N. Petrov National Medical Research Center of Oncology, N.N. Petrov National Medicine Research Center of Oncology, Pavlov First Saint Petersburg State Medical University,
Abstract
De-escalating therapy dilemma in small HER2 positive node negative breast cancer.Org: Centre Oscar Lambret,
Abstract
TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC).Org: Department of oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, Department of Breast Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Department of Breast Medicine, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China, Harbin Medical University Cancer Hospital, Harbin, China, Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China,
Abstract
Practice patterns in ongoing neoadjuvant ATNEC trial for patients with cT1-3N1M0 breast cancer: Response to neoadjuvant chemotherapy (NACT), targeted axillary dissection and breast conservation rates.Org: Royal Derby Hospital, University of Warwick, Royal Cornwall Hospitals NHS Trust, Aberdeen Royal Infirmary, NCRI Breast Clinical Studies Group,
Abstract
Luminal and basal subtyping of circulating tumor cells and influence on outcomes in patients with metastatic castration-resistant prostate cancer.Org: Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Division of Cancer Systems Biology, Department of Surgery, Brigham and Women's Hospital, Boston, MA, California NanoSystems Institute, University of California,
Abstract
Outcomes of myeloid malignancies in patients previously treated with PARP inhibitors for solid malignancies: A single institution experience.Org: University of Texas MD Anderson Cancer Center, The University of Texas at MD Anderson Cancer Center, MD Anderson Cancer Center, Department of Leukemia,
Abstract
Efficacy comparison of anthracycline and taxane when added to immune checkpoint inhibitor in neoadjuvant chemotherapy of triple negative breast cancer: Clinical evidence from size-reduction measurement by ultrasound.Org: Chang Gung Memorial Hospital at Taipei, Chang Gung University Medical College, Chang Gung Memorial Hospital, Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL,
Abstract
Recurrent versus non-recurrent triple negative breast cancer: An institutional study.Org: Geisinger Northeast, Wilkes Barre, PainReform, The Pennsylvania State University, State College,
Abstract
ADC vs HP dual-antibody for HER2-positive advanced breast cancer after failed to TKI.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China, Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China, Department of Breast Cancer, the Fifth Medical Center Affiliated to PLA General Hospital, Beijing, China,
Abstract
Costs and health care resource utilization (HCRU) for patients with advanced biliary tract (aBTC) cancer using administrative databases in Ontario, 2010 to 2020.Org: Sunnybrook Research Institute, AstraZeneca Canada, University Health Network,
Abstract
High-throughput drug screening (HTDS) of patient-derived tumor organoids (PTDO) from advanced gastrointestinal malignancies: Response and identification of novel therapeutic options.Org: Weill Cornell Medical College University, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, NewYork-Presbyterian/Weill Cornell Medical Center, Joan and Sanford I Weill Medical College of Cornell University, NYP/Columbia,
Abstract
Canadian (CAN) real-world outcomes for relapsed/recurrent (R/R) metastatic triple-negative breast cancer (mTNBC) in the first-line or later (1L+) setting by early or late recurrence status.Org: Gilead Sciences Canada, University of Calgary, Gilead Sciences Europe Ltd.,